TPM3-NTRK1 Fusion Cervical Sarcoma: A Case Report of a Novel Subset of Gynaecological Sarcomas and Successful Treatment of Recurrent Disease With Trk-Inhibition Therapy

Neurotrophic tyrosine kinase receptor (<i>NTRK</i>) activation by neurotrophins has been shown to promote cellular proliferation, differentiation, and survival by preventing apoptosis. <i>NTRK</i> gene fusions are rare in gynaecological cancer. This case report describes the successful management of a metastatic <i>NTRK</i>-positive cervical sarcoma using Trk-inhibition therapy, following recurrence after surgical interventions and chemotherapy. The patient was administered 31 cycles of 100 mg larotrectinib (Vitrakvi) twice daily. The patient remains stable with no evidence of local, nodal, or metastatic disease for more than three years following the initial presentation. This report aims to propose the use of larotrectinib as a management option for recurrent <i>NTRK</i>-positive cervical sarcomas.